 |
97 Diseases |  |
247 Trials |
|
247 Trials |  |
14602 News |  |
| «12...159160161162163164165166167168169170171» |
- |||||||||| Xarelto (rivaroxaban) / J&J
New P3 trial: RASET: Rivaroxaban Anticoagulation for Superficial Vein Thrombosis (clinicaltrials.gov) - Apr 22, 2014
P3, N=600, Not yet recruiting, Sponsor: McMaster University
- || rivaroxaban / Generic mfg.
Trial initiation date: Patient and Physician Knowledge of Key Safety Messages (clinicaltrials.gov) - Apr 21, 2014
P=N/A, N=4000, Not yet recruiting, Sponsor: Bayer
Initiation date: Mar 2014 --> Jun 2014
- || rivaroxaban / Generic mfg.
Enrollment closed: XALIA: Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy (clinicaltrials.gov) - Apr 21, 2014
P=N/A, N=4800, Active, not recruiting, Sponsor: Bayer
Initiation date: Mar 2014 --> Jun 2014 Recruiting --> Active, not recruiting
- | Xarelto (rivaroxaban) / J&J
New P4 trial: RAPS: Rivaroxaban for Antiphospholipid Antibody Syndrome (clinicaltrials.gov) - Apr 14, 2014
P4, N=150, Not yet recruiting, Sponsor: St. Joseph's Healthcare Hamilton
- || rivaroxaban / Generic mfg.
Enrollment closed: XANTUS: Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation (clinicaltrials.gov) - Apr 13, 2014
P=N/A, N=6000, Active, not recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| rivaroxaban / Generic mfg.
New P3 trial: MARINER: A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients (clinicaltrials.gov) - Apr 9, 2014
P3, N=8000, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- ||| rivaroxaban / Generic mfg.
Clinical: BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies (clinicaltrials.gov) - Mar 16, 2014
P=N/A, N=600, Recruiting, Sponsor: Bayer
- |||||| rivaroxaban / Generic mfg.
Clinical: Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism) (clinicaltrials.gov) - Mar 16, 2014
P3, N=2850, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Savaysa (edoxaban) / Daiichi Sankyo
Trial initiation date: Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis (clinicaltrials.gov) - Feb 27, 2014
P=N/A, N=56, Not yet recruiting, Sponsor: Medical College of Wisconsin
Not yet recruiting --> Recruiting Initiation date: Jan 2014 --> Apr 2014
- rivaroxaban / Generic mfg.
New P2 trial: The Effect of Rivaroxaban in Sickle Cell Disease (clinicaltrials.gov) - Feb 24, 2014
P2, N=34, Enrolling by invitation, Sponsor: University of North Carolina, Chapel Hill
- ||||| rivaroxaban / Generic mfg.
New P4 trial: Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification (clinicaltrials.gov) - Feb 17, 2014
P4, N=348, Recruiting, Sponsor: RWTH Aachen University
- |||||||||| rivaroxaban / Generic mfg.
New P3 trial: Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism) (clinicaltrials.gov) - Feb 13, 2014
P3, N=2850, Recruiting, Sponsor: Bayer
- rivaroxaban / Generic mfg.
New P1 trial, Surgery, Bariatric surgery: Rivaroxaban Effects in Subjects Who Have Undergone Gastric Bypass Surgery (clinicaltrials.gov) - Feb 5, 2014
P1, N=48, Not yet recruiting, Sponsor: State University of New York - Upstate Medical University
- | rivaroxaban / Generic mfg., warfarin / Generic mfg.
New P4 trial: Evaluation of Wound Drainage After Knee or Hip Arthroplasty (clinicaltrials.gov) - Feb 2, 2014
P4, N=300, Not yet recruiting, Sponsor: University of Michigan
- rivaroxaban / Generic mfg.
New P4 trial: Dose-finding of Rivaroxaban in Hemodialysis (clinicaltrials.gov) - Jan 26, 2014
P4, N=12, Recruiting, Sponsor: AZ Sint-Jan AV
- ||||||| rivaroxaban / Generic mfg.
Trial completion: X-VERT: Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion (clinicaltrials.gov) - Jan 26, 2014
P3, N=1504, Completed, Sponsor: Bayer
Initiation date: Jan 2014 --> Apr 2014 Active, not recruiting --> Completed
- ||||| rivaroxaban / Generic mfg., warfarin / Generic mfg.
New P2 trial: TripleAXEL: Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation (clinicaltrials.gov) - Jan 21, 2014
P2, N=196, Not yet recruiting, Sponsor: Asan Medical Center
- ||||||| rivaroxaban / Generic mfg.
Trial completion: Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients (clinicaltrials.gov) - Jan 8, 2014
P3, N=60, Completed, Sponsor: Bayer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | rivaroxaban / Generic mfg., warfarin / Generic mfg.
New P4 trial: Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation Study (REWRAPS) (clinicaltrials.gov) - Dec 29, 2013
P4, N=1600, Not yet recruiting, Sponsor: Fujita Health University
- enoxaparin sodium / Generic mfg.
Clinical: Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis (clinicaltrials.gov) - Dec 1, 2013
P=N/A, N=56, Not yet recruiting, Sponsor: Medical College of Wisconsin
- | rivaroxaban / Generic mfg.
New P4 trial: Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer (clinicaltrials.gov) - Nov 19, 2013
P4, N=127, Recruiting, Sponsor: Seoul National University Hospital
- rivaroxaban / Generic mfg., warfarin / Generic mfg.
Enrollment open: Prevention of Recurrence After Thrombolysis in Acute Iliofemoral Venous Thrombosis (PRAIS) Study (clinicaltrials.gov) - Nov 16, 2013
P=N/A, N=72, Recruiting, Sponsor: Seoul National University Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || rivaroxaban / Generic mfg.
Enrollment change: XANAP: Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia (clinicaltrials.gov) - Nov 7, 2013
P=N/A, N=2300, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting N=5500 --> 2300
- || rivaroxaban / Generic mfg.
Trial completion: Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients (clinicaltrials.gov) - Oct 23, 2013
P3, N=40, Completed, Sponsor: Bayer
N=5500 --> 2300 Active, not recruiting --> Completed
- |||||| rivaroxaban / Generic mfg.
Enrollment open: A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure (clinicaltrials.gov) - Oct 15, 2013
P3, N=5000, Recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || rivaroxaban / Generic mfg.
Enrollment closed, Surgery, Compliance: Russian Non-Interventional Study on Compliance of Venous Thromboembolism (VTE) (clinicaltrials.gov) - Sep 29, 2013
P=N/A, N=2345, Active, not recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | GCC-4401C / GC Biopharma
New P1 trial: A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers (clinicaltrials.gov) - Sep 29, 2013
P1, N=46, Enrolling by invitation, Sponsor: Green Cross Corporation
- Trial completion, Combination therapy: Antithrombotic Triple Therapy in Humans (clinicaltrials.gov) - Sep 23, 2013
P4, N=60, Completed, Sponsor: Medical University of Vienna
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||| Xarelto (rivaroxaban) / J&J
Adverse events: Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK) (clinicaltrials.gov) - Sep 19, 2013
P=N/A, N=20000, Recruiting, Sponsor: Bayer
- ||| Xarelto (rivaroxaban) / J&J
Adverse events: Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands) (clinicaltrials.gov) - Sep 19, 2013
P=N/A, N=20000, Recruiting, Sponsor: Bayer
- ||| Xarelto (rivaroxaban) / J&J
Adverse events: Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany) (clinicaltrials.gov) - Sep 19, 2013
P=N/A, N=20000, Recruiting, Sponsor: Bayer
- |||||| rivaroxaban / Generic mfg.
Enrollment open: Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter (clinicaltrials.gov) - Aug 27, 2013
P3, N=60, Recruiting, Sponsor: Bayer
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||| rivaroxaban / Generic mfg.
Clinical: NEURO-XAR: Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients (clinicaltrials.gov) - Aug 18, 2013
P=N/A, N=214, Recruiting, Sponsor: Bayer
- || rivaroxaban / Generic mfg., aspirin / Generic mfg.
New P2/3 trial: Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events (clinicaltrials.gov) - Aug 14, 2013
P2/3, N=3700, Not yet recruiting, Sponsor: Xijing Hospital
- ||| rivaroxaban / Generic mfg.
Enrollment open: Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism (clinicaltrials.gov) - Aug 8, 2013
P=N/A, N=150, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| rivaroxaban / Generic mfg.
Enrollment open: Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT) (clinicaltrials.gov) - Aug 8, 2013
P=N/A, N=150, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| rivaroxaban / Generic mfg.
Enrollment open: XANTUS-EL: Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region (clinicaltrials.gov) - Aug 5, 2013
P=N/A, N=2500, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| rivaroxaban / Generic mfg.
Clinical: Patient and Physician Knowledge of Key Safety Messages (clinicaltrials.gov) - Jul 22, 2013
P=N/A, N=4000, Not yet recruiting, Sponsor: Bayer
- | rivaroxaban / Generic mfg.
Trial suspension, Surgery: XYRIS: Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement) (clinicaltrials.gov) - Jun 20, 2013
P=N/A, N=500, Suspended, Sponsor: Bayer
Not yet recruiting --> Recruiting Not yet recruiting --> Suspended
- rivaroxaban / Generic mfg.
Enrollment closed: A Prospective Pharmacodynamic Study of Rivaroxaban (clinicaltrials.gov) - Jun 16, 2013
P=N/A, N=65, Active, not recruiting, Sponsor: University of North Carolina, Chapel Hill
Not yet recruiting --> Suspended Recruiting --> Active, not recruiting
- ||| Xarelto (rivaroxaban) / J&J
Enrollment open, HEOR: SATORI: Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication (clinicaltrials.gov) - Jun 16, 2013
P=N/A, N=550, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| rivaroxaban / Generic mfg.
New P3 trial: A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure (clinicaltrials.gov) - Jun 12, 2013
P3, N=5000, Recruiting, Sponsor: Janssen Research & Development, LLC
- ||| rivaroxaban / Generic mfg.
Trial completion, Surgery: XAMOS: Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty (clinicaltrials.gov) - Jun 12, 2013
P=N/A, N=19076, Completed, Sponsor: Bayer
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || rivaroxaban / Generic mfg.
Enrollment closed: An Observational Post-Authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto®). (clinicaltrials.gov) - Jun 3, 2013
P=N/A, N=3400, Active, not recruiting, Sponsor: Professor Saad Shakir
Active, not recruiting --> Completed Not yet recruiting --> Active, not recruiting
- |||||| rivaroxaban / Generic mfg.
Enrollment open: PIONEER AF-PCI: A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention (clinicaltrials.gov) - May 28, 2013
P3, N=2169, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | rivaroxaban / Generic mfg.
New P1 trial: Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet (clinicaltrials.gov) - May 13, 2013
P1, N=14, Completed, Sponsor: Bayer
- ||| rivaroxaban / Generic mfg.
Enrollment open, HEOR: SAFARI: Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication (clinicaltrials.gov) - Apr 29, 2013
P=N/A, N=550, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| rivaroxaban / Generic mfg.
New P3 trial: Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter (clinicaltrials.gov) - Apr 22, 2013
P3, N=60, Recruiting, Sponsor: Bayer
- ||||| rivaroxaban / Generic mfg.
Enrollment change: VENTURE-AF: A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy (clinicaltrials.gov) - Apr 14, 2013
P3, N=200, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
Not yet recruiting --> Recruiting N=250 --> 200
- |||||||||| rivaroxaban / Generic mfg.
New P3 trial: PIONEER AF-PCI: A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention (clinicaltrials.gov) - Apr 10, 2013
P3, N=2169, Recruiting, Sponsor: Janssen Scientific Affairs, LLC